Endocrine

pp 1–11 | Cite as

Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy

  • Rebecca J. Brown
  • Elif A. Oral
  • Elaine Cochran
  • David Araújo-Vilar
  • David B. Savage
  • Alison Long
  • Gregory Fine
  • Taylor Salinardi
  • Phillip Gorden
Original Article
  • 24 Downloads

Abstract

Purpose

The purpose of this study is to summarize the effectiveness and safety of metreleptin in patients with congenital or acquired generalized lipodystrophy.

Methods

Patients (n = 66) aged ≥6 months had lipodystrophy, low circulating leptin, and ≥1 metabolic abnormality (diabetes mellitus, insulin resistance, or hypertriglyceridemia). Metreleptin dose (once or twice daily) was titrated to a mean dose of 0.10 mg/kg/day with a maximum of 0.24 mg/kg/day. Means and changes from baseline to month 12 were assessed for glycated hemoglobin (HbA1c), fasting triglycerides (TGs), and fasting plasma glucose (FPG). Additional assessments included the proportions of patients achieving target decreases in HbA1c or fasting TGs at months 4, 12, and 36, medication changes, and estimates of liver size. Treatment-emergent adverse events (TEAEs) were recorded.

Results

Significant mean reductions from baseline were seen at month 12 for HbA1c (–2.2%, n = 59) and FPG (–3.0 mmol/L, n = 59) and mean percent change in fasting TGs (–32.1%, n = 57) (all p ≤ 0.001). Reductions from baseline over time in these parameters were also significant at month 36 (all p < 0.001, n = 14). At month 4, 34.8% of patients had a ≥1% reduction in HbA1c and 62.5% had a ≥30% reduction in fasting TGs; at month 12, 80% of patients had a ≥1% decrease in HbA1c or ≥30% decrease in TGs, and 66% had a decrease of ≥2% in HbA1c or ≥40% decrease in TGs. Of those on medications, 41%, 22%, and 24% discontinued insulin, oral antidiabetic medications, or lipid-lowering medications, respectively. Mean decrease in liver volume at month 12 was 33.8% (p < 0.001, n = 12). Most TEAEs were of mild/moderate severity.

Conclusions

In patients with generalized lipodystrophy, long-term treatment with metreleptin was well tolerated and resulted in sustained improvements in hypertriglyceridemia, glycemic control, and liver volume.

Keywords

Diabetes Insulin resistance Leptin Lipodystrophy Metreleptin 

Notes

Acknowledgements

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript and take responsibility for the integrity of the work as a whole. Aegerion Pharmaceuticals provided funding for medical writing and/or editing support in the development of this manuscript; Jennifer L. Giel, Ph.D., of inScience Communications, Springer Healthcare (Philadelphia, PA, USA), based on input from authors, wrote the first draft and revised subsequent drafts of the manuscript, and Adrienne M. Schreiber of inScience Communications, Springer Healthcare (Philadelphia, PA, USA) copyedited and styled the manuscript per journal requirements. Aegerion Pharmaceuticals reviewed and provided feedback to the authors. The authors had full editorial control of the manuscript and provided their final approval of all content. Jean-Karl Sirois provided statistical analyses on behalf of Veristat LLC, Montreal, Canada, which was funded by Aegerion Pharmaceuticals, Inc. The authors acknowledge the services of the Clinical Core Laboratory of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health for measurement of leptin levels.

Funding

This work was supported by the intramural research program of the National Institute of Diabetes and Digestive and Kidney Diseases. E.A.O. is supported by NIH grant RO-1 DK-088114 as well as UM Lipodystrophy Fund donated by the Sopha Family and White Point Foundation of Turkey.

Compliance with ethical standards

Conflict of interest

E.A.O. has served as a consultant to Aegerion, Akcea, AstraZeneca, and Regeneron, received grants from Aegerion, Akcea, AstraZeneca, Gemphire, GIDynamics, and received non-material support from Aegerion and Boehringer Ingelheim. D.A.V. and D.B.S. have served as consultants to Aegerion Pharmaceuticals. A.L. and G.F. are employees of Aegerion Pharmaceuticals. T.S. is a former employee of Aegerion Pharmaceuticals. R.J.B., E.C., and P.G. declares that they have no conflict of interest.

Supplementary material

12020_2018_1589_MOESM1_ESM.pdf (17 kb)
Supplementary Information

References

  1. 1.
    R.J. Brown, D. Araujo-Vilar, P.T. Cheung, D. Dunger, A. Garg, M. Jack, L. Mungai, E.A. Oral, N. Patni, K.I. Rother, J. von Schnurbein, E. Sorkina, T. Stanley, C. Vigouroux, M. Wabitsch, R. Williams, T. Yorifuji, The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J. Clin. Endocrinol. Metab. 101, 4500–4511 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    W.A. Haque, I. Shimomura, Y. Matsuzawa, A. Garg, Serum adiponectin and leptin levels in patients with lipodystrophies. J. Clin. Endocrinol. Metab. 87, 2395 (2002)CrossRefPubMedGoogle Scholar
  3. 3.
    Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, J.M. Friedman, Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432 (1994)CrossRefPubMedGoogle Scholar
  4. 4.
    Y. Handelsman, E.A. Oral, Z.T. Bloomgarden, R.J. Brown, J.L. Chan, D. Einhorn, A.J. Garber, A. Garg, W.T. Garvey, G. Grunberger, R.R. Henry, N. Lavin, C.D. Tapiador, C. Weyer, The clinical approach to the detection of lipodystrophy—an AACE consensus statement. Endocr. Pract. 19, 107–116 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    A. Bingham, G. Mamyrova, K.I. Rother, E. Oral, E. Cochran, A. Premkumar, D. Kleiner, L. James-Newton, I.N. Targoff, J.P. Pandey, D.M. Carrick, N. Sebring, T.P. O’Hanlon, M. Ruiz-Hidalgo, M. Turner, L.B. Gordon, J. Laborda, S.R. Bauer, P.J. Blackshear, L. Imundo, F.W. Miller, L.G. Rider, Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine 87, 70–86 (2008)CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    E.A. Oral, Lipoatrophic diabetes and other related syndromes. Rev. Endocr. Metab. Disord. 4, 61–77 (2003)CrossRefPubMedGoogle Scholar
  7. 7.
    A. Garg, Acquired and inherited lipodystrophies. N. Engl. J. Med. 350, 1220–1234 (2004)CrossRefPubMedGoogle Scholar
  8. 8.
    C.A. Meehan, E. Cochran, A. Kassai, R.J. Brown, P. Gorden, Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev. Clin. Pharmacol. 9, 59–68 (2016)CrossRefPubMedGoogle Scholar
  9. 9.
    N. Patni, A. Garg, Congenital generalized lipodystrophies—new insights into metabolic dysfunction. Nat. Rev. Endocrinol. 11, 522–534 (2015)CrossRefPubMedGoogle Scholar
  10. 10.
    M. Miller, N.J. Stone, C. Ballantyne, V. Bittner, M.H. Criqui, H.N. Ginsberg, A.C. Goldberg, W.J. Howard, M.S. Jacobson, P.M. Kris-Etherton, T.A. Lennie, M. Levi, T. Mazzone, S. Pennathur, Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123, 2292–2333 (2011)CrossRefPubMedGoogle Scholar
  11. 11.
    K. Chou, C.M. Perry, Metreleptin: first global approval. Drugs 73, 989–997 (2013)CrossRefPubMedGoogle Scholar
  12. 12.
    Myalept [Package Insert] (Aegerion Pharmaceuticals, Inc., Cambridge, MA, 2015)Google Scholar
  13. 13.
    J.L. Chan, K. Lutz, E. Cochran, W. Huang, Y. Peters, C. Weyer, P. Gorden, Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr. Pract. 17, 922–932 (2011)CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    A.Y. Chong, B.C. Lupsa, E.K. Cochran, P. Gorden, Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 53, 27–35 (2010)CrossRefPubMedGoogle Scholar
  15. 15.
    J.D. Christensen, A.O. Lungu, E. Cochran, M.T. Collins, R.I. Gafni, J.C. Reynolds, K.I. Rother, P. Gorden, R.J. Brown, Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J. Clin. Endocrinol. Metab. 99, E1493–E1500 (2014)CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    T. Diker-Cohen, E. Cochran, P. Gorden, R.J. Brown, Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J. Clin. Endocrinol. Metab. 100, 1802–1810 (2015)CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    J. Joseph, R.D. Shamburek, E.K. Cochran, P. Gorden, R.J. Brown, Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides. J. Clin. Endocrinol. Metab. 99, E1676–E1680 (2014)CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    F. Kamran, K.I. Rother, E. Cochran, E. Safar Zadeh, P. Gorden, R.J. Brown, Consequences of stopping and restarting leptin in an adolescent with lipodystrophy. Horm. Res. Paediatr. 78, 320–325 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    R. Muniyappa, B.S. Abel, A. Asthana, M.F. Walter, E.K. Cochran, A.T. Remaley, M.C. Skarulis, P. Gorden, R.J. Brown, Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy. J. Clin. Lipidol. 11, 543–550 (2017)CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    E.A. Oral, V. Simha, E. Ruiz, A. Andewelt, A. Premkumar, P. Snell, A.J. Wagner, A.M. DePaoli, M.L. Reitman, S.I. Taylor, P. Gorden, A. Garg, Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346, 570–578 (2002)CrossRefPubMedGoogle Scholar
  21. 21.
    K. Ebihara, T. Kusakabe, M. Hirata, H. Masuzaki, F. Miyanaga, N. Kobayashi, T. Tanaka, H. Chusho, T. Miyazawa, T. Hayashi, K. Hosoda, Y. Ogawa, A.M. DePaoli, M. Fukushima, K. Nakao, Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J. Clin. Endocrinol. Metab. 92, 532–541 (2007)CrossRefPubMedGoogle Scholar
  22. 22.
    C. Vatier, S. Fetita, P. Boudou, C. Tchankou, L. Deville, J. Riveline, J. Young, L. Mathivon, F. Travert, D. Morin, J. Cahen, O. Lascols, F. Andreelli, Y. Reznik, E. Mongeois, I. Madelaine, M. Vantyghem, J. Gautier, C. Vigouroux, One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes. Diabetes Obes. Metab. 18, 693–697 (2016)CrossRefPubMedGoogle Scholar
  23. 23.
    D. Araujo-Vilar, S. Sanchez-Iglesias, C. Guillin-Amarelle, A. Castro, M. Lage, M. Pazos, J.M. Rial, J. Blasco, E. Guillen-Navarro, R. Domingo-Jimenez, M.R. del Campo, B. Gonzalez-Mendez, F.F. Casanueva, Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience. Endocrine 49, 139–147 (2015)CrossRefPubMedGoogle Scholar
  24. 24.
    C. Musso, M.L. Major, E. Andres, V. Simha, Metreleptin treatment in three patients with generalized lipodystrophy. Clin. Med. Insights Case Rep. 9, 123–127 (2016)CrossRefPubMedGoogle Scholar
  25. 25.
    J. Beltrand, M. Beregszaszi, D. Chevenne, G. Sebag, M. De Kerdanet, F. Huet, M. Polak, N. Tubiana-Rufi, D. Lacombe, A.M. De Paoli, C. Levy-Marchal, Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. Pediatrics 120, e291–e296 (2007)CrossRefPubMedGoogle Scholar
  26. 26.
    R.J. Brown, J.L. Chan, E.S. Jaffe, E. Cochran, A.M. DePaoli, J.F. Gautier, C. Goujard, C. Vigouroux, P. Gorden, Lymphoma in acquired generalized lipodystrophy. Leuk. Lymphoma 57, 45–50 (2016)CrossRefPubMedGoogle Scholar
  27. 27.
    A.V. Hernandez, V. Pasupuleti, V.A. Benites-Zapata, P. Thota, A. Deshpande, F.R. Perez-Lopez, Insulin resistance and endometrial cancer risk: a systematic review and meta-analysis. Eur. J. Cancer 51, 2747–2758 (2015)CrossRefPubMedGoogle Scholar
  28. 28.
    B. Arcidiacono, S. Iiritano, A. Nocera, K. Possidente, M.T. Nevolo, V. Ventura, D. Foti, E. Chiefari, A. Brunetti, Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp. Diabetes Res. 2012, 789174 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    X. Wang, M.F. Haring, T. Rathjen, S.M. Lockhart, D. Sorensen, S. Ussar, L.M. Rasmussen, M.M. Bertagnolli, C.R. Kahn, C. Rask-Madsen, Insulin resistance in vascular endothelial cells promotes intestinal tumour formation. Oncogene 36, 4987–4996 (2017)CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2018

Authors and Affiliations

  • Rebecca J. Brown
    • 1
  • Elif A. Oral
    • 2
  • Elaine Cochran
    • 1
  • David Araújo-Vilar
    • 3
  • David B. Savage
    • 4
  • Alison Long
    • 5
  • Gregory Fine
    • 5
  • Taylor Salinardi
    • 5
  • Phillip Gorden
    • 1
  1. 1.National Institute of Diabetes and Digestive and Kidney DiseasesNational Institutes of HealthBethesdaUSA
  2. 2.Department of Internal MedicineUniversity of Michigan Medical School and Health SystemsAnn ArborUSA
  3. 3.Department of MedicineUniversity of Santiago de CompostelaSantiago de CompostelaSpain
  4. 4.The University of Cambridge Metabolic Research LaboratoriesWellcome Trust-MRC Institute of Metabolic ScienceCambridgeUK
  5. 5.Aegerion PharmaceuticalsCambridgeUSA

Personalised recommendations